Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 9, Issue 12, Pages 1553-1563Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712590903449222
Keywords
acromegaly; diabetic nephropathy; diabetic retinopathy; GH antagonist; growth hormone receptor antagonist; growth hormone secretory reserve
Funding
- National Institute for Health Research [NF-SI-0508-10274] Funding Source: researchfish
Ask authors/readers for more resources
Background: Pegvisomant is a genetically engineered molecule, which exhibits specific growth hormone (GH) antagonism by directly interacting with the GH receptor. It is currently licensed for the treatment of acromegaly where surgery and medical therapy with somatostatin analogues have failed. Objective: To delineate the role of pegvisomant in the treatment of acromegaly and its novel application in other areas of clinical medicine where suppression of GH action may be of therapeutic benefit. Methods: A literature review from PubMed- and EMBASE-listed publications and the web-sites of licensing organisations for medicinal products. Conclusion: Pegvisomant is currently used as a second line therapy in the management of acromegaly. It is highly effective in suppressing the metabolic effects of elevated GH levels when used alone or in combination with somatostatin analogues. However, its long term efficacy and safety for this indication has yet to be established. Preliminary data indicate that pegvisomant may have a role in management of type 1 diabetes with beneficial effects on insulin sensitivity and in preventing the progression of microvascular complications. Additional roles as an adjunct to cancer chemotherapy regimens and for the diagnosis of GH deficiency have been proposed, but have yet to be confirmed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available